Pregnancy: A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/neonatal toxicity of desloratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see PHARMACOLOGY: Toxicology: Preclinical safety data under Actions). As a precautionary measure, it is preferable to avoid the use of desloratadine during pregnancy.
Breast-feeding: Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from desloratadine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility: There are no data available on male and female fertility.
Other Services
Country
Account